Zenas Biopharma's Purchased 60,000: Insider Buy Deep Dive
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Learn practical ways to evaluate budgeting success and understand key indicators of progress. Use simple metrics to validate how your budget aligns with your goals.
13,940 articlesA biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Biotech investing often feels unpredictable. This year, agios stock down year highlights how big investor moves and l...
A sudden 47% rise in Structure Therapeutics stock has traders buzzing while a major fund exits a multi-million dollar...
Snap is playing a high-stakes game. This article breaks down snap’s specs gamble, what it would take for AR hardware ...
A sharp rise in foreclosure activity points to growing distress and new chances for investors. Learn what the foreclo...
A fund’s big move out of a top-performing pharma stock can puzzle investors. Here’s a clear, practical look at what k...
Two fast-food giants shape the investing landscape with very different revenue engines. This analysis dives into how ...
Small, nearly unknown biotech stocks can surge when their pipeline milestones hit. This guide breaks down how to spot...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Archer Aviation rode the eVTOL thrill, but reality check milestones have tempered the hype. This guide helps you deci...
A major advisory firm made a multi-million dollar bet in a large-cap growth ETF, catching the eye of everyday investo...
As Daré gears up to discuss Q1 2026 results, investors will scrutinize cash runway, pipeline milestones, and strategi...